300966.SZ
共同药业
SZSE · Healthcare · C 制造业 · CN
CNY 24.31
−3.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 628.9M | 606.2M | 536.6M | 566.4M | 604.6M |
| Cost of Revenue | 542.2M | 522.7M | 431.0M | 441.3M | 466.4M |
| Gross Profit | 86.7M | 83.5M | 105.6M | 125.1M | 138.2M |
| Operating Expenses | |||||
| R&D Expense | 68.3M | 69.9M | 51.1M | 38.1M | 45.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 54.1M | 56.9M | 61.0M | 44.4M | 38.8M |
| Selling & Marketing Expense | 8.5M | 8.8M | 6.9M | 7.1M | 4.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 185.3M | 186.0M | 142.7M | 100.9M | 99.7M |
| Cost and Expenses | 727.5M | 708.7M | 573.8M | 542.2M | 566.1M |
| Operating Income (EBIT) | (97.9M) | (101.0M) | (42.4M) | 19.5M | 38.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (102.1M) | (105.2M) | (45.5M) | 19.1M | 38.5M |
| Income Tax Expense | (22.3M) | (23.5M) | (13.9M) | (2.2M) | (999.7K) |
| Bottom Line | |||||
| Net Income | (71.2M) | (73.4M) | (27.6M) | 23.0M | 40.2M |
| Earnings from Cont. Ops | (79.8M) | (81.7M) | (31.7M) | 21.3M | 39.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (71.2M) | (73.4M) | (27.6M) | 23.0M | 40.2M |
| Per Share | |||||
| Basic EPS | (CN¥0.62) | (CN¥0.64) | (CN¥0.24) | CN¥0.20 | CN¥0.35 |
| Diluted EPS | (CN¥0.62) | (CN¥0.64) | (CN¥0.24) | CN¥0.20 | CN¥0.35 |
| Revenue Per Share | CN¥5.90 | CN¥5.29 | CN¥4.67 | CN¥4.92 | CN¥5.26 |
| Shares | |||||
| Basic Shares Outstanding | 106.6M | 114.6M | 115.0M | 115.0M | 114.9M |
| Diluted Shares Outstanding | 106.6M | 114.6M | 115.0M | 115.0M | 114.9M |
| Profitability Metrics | |||||
| EBITDA | — | 17.7M | 3.9M | 48.8M | 64.0M |
| D&A | — | 118.7M | 46.3M | 29.3M | 25.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026